Drugs / LENVERVIMAB
LENVERVIMAB
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02569372 | Nov 2015 → Oct 2017 | chronic hepatitis B virus infection | Green Cross Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01606163 | Aug 2012 → Jun 2013 | hepatitis B virus infection | Green Cross Corporation | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03801798 | Feb 2019 → Dec 2021 | chronic hepatitis B virus infection | Green Cross Corporation | Unknown | No outcome recorded |
| Phase 2 | NCT02304315 | Feb 2015 → May 2016 | hepatitis B virus infection | Green Cross Corporation | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03519113 | Mar 2018 → Mar 2022 | hepatitis B virus infection | Green Cross Corporation | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LENVERVIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068606 ↗ |
| Known as | GC1102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02304315 ↗ |
| Known as | HBIg | “GC1102 is a new recombinant hepatitis B immunoglobulin (HBIg) from Chinese Hamster Ovary (CHO) cells.” NCT02304315 ↗ |
| Modality | Monoclonal antibody | “It is a monoclonal antibody” NCT02304315 ↗ |
| Route | Intravenous | “GC1102 IV bolus injection during 10\~ 30 seconds.” NCT01606163 ↗ |